Find a Clinical Trial

For many patients with difficult-to-treat cancers, the options have been limited. Verastem Oncology aims to change that by developing and commercializing new medicines for patients diagnosed with RAS/MAPK-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. Find out more about our clinical trials here.
Verastem-Sponsored Trials –
RAMP 203: A Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib +/- Defactinib in Patients with KRAS G12C-Mutated NSCLC
Non-Small Cell Lung Cancer
RAMP 205: A Study of Avutometinib (VS-6766) + Defactinib with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
Pancreatic Cancer
RAMP 201 (ENGOTov60/GOG3052: A Phase 2 Study of Avutometinib (VS-6766) v Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS mutation
Low-Grade Serous Ovarian Cancer
RAMP 301 (GOG-097/ENGOTov81): A Phase 3 Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low-Grade Serous Ovarian Cancer
VS-7375-101: A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Advanced solid tumors harboring KRAS G12D mutations
Investigator-Sponsored Studies +
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Mesonephric Gynecologic Cancer
A Phase 2 Study of Avutometinib (VS-6766) + Defactinib in Patients with Gynecologic Cancers
Endometrioid Cancer
A Study of Avutometinib (VS-6766) and Cetuximab in Patients with Advanced Colorectal Cancer
Colorectal Cancer
FRAME: A Phase I Study of Avutometinib (VS-6766) + Defactinib in Patients with Advanced Solid Tumors
Low-Grade Serous Ovarian Cancer
A Phase I/II Study of Avutometinib (VS-6766) + Abemaciclib + Fulvestrant in Patients with HR+/HER2-Negative Breast Cancer
Breast Cancer
A Phase I Trial of Avutometinib (VS-6766) monotherapy and in Combination with Everolimus in Patients with BRAF, KRAS and NRAS-Mutant Solid Tumors
Lung Cancer